UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

A number of people — including teenagers — are developing kidney stones. But, the chances of developing kidney stones can be reduced by what goes into the body.

To assess whether the kidney microbiome affects stone formation, the researchers cultured bacteria in special chambers that simulate urinary flow within the kidneys. They then introduced calcium ...

If these get out of range, your doctor may test your urine to see why your calcium is low. And if they suspect kidney or bone problems, they'll likely do more testing. If you have ...

LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...